{"id":39097,"date":"2025-08-12T14:49:02","date_gmt":"2025-08-12T06:49:02","guid":{"rendered":"https:\/\/flcube.com\/?p=39097"},"modified":"2025-08-12T14:49:03","modified_gmt":"2025-08-12T06:49:03","slug":"takeda-reports-q1-fy2025-revenue-dip-led-by-fx-headwinds-and-generic-competition","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=39097","title":{"rendered":"Takeda Reports Q1 FY2025 Revenue Dip Led by FX Headwinds and Generic Competition"},"content":{"rendered":"\n<p>Japan-based Takeda Pharmaceutical (<a href=\"https:\/\/www.google.com\/finance\/quote\/4502:TYO\">TYO: 4502<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/TAK:NYSE\">NYSE: TAK<\/a>)\u00a0 reported financial results for the first quarter of fiscal year 2025 (FY2025Q1, April 1, 2025~June 30, 2025). Revenue for the quarter decreased 3.7% year-over-year (YOY) at constant exchange rates (CER) to JPY 1,106.7 billion (USD 7.46 billion). Core operating profit was JPY 321.8 billion (USD 2.17 billion), representing an 11.9% YOY drop.<\/p>\n\n\n\n<p><strong>Decline Factors<\/strong><br>The revenue and core operating profit decline compared to the same period last fiscal year was primarily due to unfavorable foreign exchange rates and generic competition. Takeda noted that despite these impacts, the overall performance remained in line with the company&#8217;s expectations for the quarter. The company anticipates that these impacts will gradually diminish in the coming quarters, and its full-year outlook released in May remains unchanged.<\/p>\n\n\n\n<p><strong>Product Sales Performance<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>GI (Gastrointestinal and Inflammation)<\/strong>: Revenue was JPY 339.3 billion (+2.6%), driven by Entyvio (vedolizumab) for ulcerative colitis (UC) and Crohn\u2019s disease (CD), with sales at JPY 232.5 billion (+4.9%).<\/li>\n\n\n\n<li><strong>Rare Diseases<\/strong>: Revenue was JPY 196.4 billion (+3.0%), led by Takhzyro (lanadelumab) with sales of JPY 55.1 billion (+3.7%).<\/li>\n\n\n\n<li><strong>PDT (Plasma-Derived Therapies)<\/strong>: Revenue was JPY 260.9 billion (+1.7%), with immunoglobulin products contributing JPY 194.0 billion (+2.0%).<\/li>\n\n\n\n<li><strong>Oncology<\/strong>: Revenue was JPY 138.8 billion (+1.8%), with Adcetris (Brentuximab Vedotin) for malignant lymphomas up 13.2%.<\/li>\n\n\n\n<li><strong>Vaccines<\/strong>: Revenue declined 6.2% to JPY 11.5 billion, primarily due to a decrease in Qdenga sales.<\/li>\n\n\n\n<li><strong>Neuroscience<\/strong>: Revenue dropped 32.6% YOY, largely due to the continued impact of generic competition on Vyvanse\/Elvanse (-46.9%) for attention deficit hyperactivity disorder (ADHD).<\/li>\n<\/ul>\n\n\n\n<p><strong>R&amp;D Milestones<\/strong><br>Takeda achieved several key milestones across its global R&amp;D pipeline, reinforcing its long-term growth trajectory. Notably, two pivotal Phase 3 studies of oveporexton (TAK-861) for Narcolepsy Type 1 (NT1) delivered positive results, meeting all primary and secondary endpoints.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/qr2025_q1_p01_en.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of qr2025_q1_p01_en.\"><\/object><a id=\"wp-block-file--media-0425509c-271f-4e56-a6ca-e6c8a8774ded\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/qr2025_q1_p01_en.pdf\">qr2025_q1_p01_en<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/qr2025_q1_p01_en.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-0425509c-271f-4e56-a6ca-e6c8a8774ded\">Download<\/a><\/div>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/qr2025_q1_er_en.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of qr2025_q1_er_en.\"><\/object><a id=\"wp-block-file--media-2f1dd673-d20b-4e12-91e0-027d6f3b63a5\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/qr2025_q1_er_en.pdf\">qr2025_q1_er_en<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/qr2025_q1_er_en.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-2f1dd673-d20b-4e12-91e0-027d6f3b63a5\">Download<\/a><\/div>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/qr2025_q1_qfr_en.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of qr2025_q1_qfr_en.\"><\/object><a id=\"wp-block-file--media-d12abd74-9de1-49ce-822f-5fa1b4ef2f4d\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/qr2025_q1_qfr_en.pdf\">qr2025_q1_qfr_en<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/qr2025_q1_qfr_en.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-d12abd74-9de1-49ce-822f-5fa1b4ef2f4d\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Japan-based Takeda Pharmaceutical (TYO: 4502, NYSE: TAK)\u00a0 reported financial results for the first quarter of&#8230;<\/p>\n","protected":false},"author":1,"featured_media":39101,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[27,874,345,1141],"class_list":["post-39097","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-finanical-reports","tag-nyse-tak","tag-takeda","tag-tyo-4502"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Takeda Reports Q1 FY2025 Revenue Dip Led by FX Headwinds and Generic Competition - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Japan-based Takeda Pharmaceutical (TYO: 4502, NYSE: TAK)\u00a0 reported financial results for the first quarter of fiscal year 2025 (FY2025Q1, April 1, 2025~June 30, 2025). Revenue for the quarter decreased 3.7% year-over-year (YOY) at constant exchange rates (CER) to JPY 1,106.7 billion (USD 7.46 billion). Core operating profit was JPY 321.8 billion (USD 2.17 billion), representing an 11.9% YOY drop.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=39097\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Takeda Reports Q1 FY2025 Revenue Dip Led by FX Headwinds and Generic Competition\" \/>\n<meta property=\"og:description\" content=\"Japan-based Takeda Pharmaceutical (TYO: 4502, NYSE: TAK)\u00a0 reported financial results for the first quarter of fiscal year 2025 (FY2025Q1, April 1, 2025~June 30, 2025). Revenue for the quarter decreased 3.7% year-over-year (YOY) at constant exchange rates (CER) to JPY 1,106.7 billion (USD 7.46 billion). Core operating profit was JPY 321.8 billion (USD 2.17 billion), representing an 11.9% YOY drop.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=39097\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-12T06:49:02+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-08-12T06:49:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/1212.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39097#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39097\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Takeda Reports Q1 FY2025 Revenue Dip Led by FX Headwinds and Generic Competition\",\"datePublished\":\"2025-08-12T06:49:02+00:00\",\"dateModified\":\"2025-08-12T06:49:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39097\"},\"wordCount\":300,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39097#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/1212.webp\",\"keywords\":[\"Finanical Reports\",\"NYSE: TAK\",\"Takeda\",\"TYO: 4502\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=39097#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39097\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=39097\",\"name\":\"Takeda Reports Q1 FY2025 Revenue Dip Led by FX Headwinds and Generic Competition - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39097#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39097#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/1212.webp\",\"datePublished\":\"2025-08-12T06:49:02+00:00\",\"dateModified\":\"2025-08-12T06:49:03+00:00\",\"description\":\"Japan-based Takeda Pharmaceutical (TYO: 4502, NYSE: TAK)\u00a0 reported financial results for the first quarter of fiscal year 2025 (FY2025Q1, April 1, 2025~June 30, 2025). Revenue for the quarter decreased 3.7% year-over-year (YOY) at constant exchange rates (CER) to JPY 1,106.7 billion (USD 7.46 billion). Core operating profit was JPY 321.8 billion (USD 2.17 billion), representing an 11.9% YOY drop.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39097#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=39097\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39097#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/1212.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/1212.webp\",\"width\":1080,\"height\":608,\"caption\":\"Takeda Reports Q1 FY2025 Revenue Dip Led by FX Headwinds and Generic Competition\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39097#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Takeda Reports Q1 FY2025 Revenue Dip Led by FX Headwinds and Generic Competition\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Takeda Reports Q1 FY2025 Revenue Dip Led by FX Headwinds and Generic Competition - Insight, China&#039;s Pharmaceutical Industry","description":"Japan-based Takeda Pharmaceutical (TYO: 4502, NYSE: TAK)\u00a0 reported financial results for the first quarter of fiscal year 2025 (FY2025Q1, April 1, 2025~June 30, 2025). Revenue for the quarter decreased 3.7% year-over-year (YOY) at constant exchange rates (CER) to JPY 1,106.7 billion (USD 7.46 billion). Core operating profit was JPY 321.8 billion (USD 2.17 billion), representing an 11.9% YOY drop.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=39097","og_locale":"en_US","og_type":"article","og_title":"Takeda Reports Q1 FY2025 Revenue Dip Led by FX Headwinds and Generic Competition","og_description":"Japan-based Takeda Pharmaceutical (TYO: 4502, NYSE: TAK)\u00a0 reported financial results for the first quarter of fiscal year 2025 (FY2025Q1, April 1, 2025~June 30, 2025). Revenue for the quarter decreased 3.7% year-over-year (YOY) at constant exchange rates (CER) to JPY 1,106.7 billion (USD 7.46 billion). Core operating profit was JPY 321.8 billion (USD 2.17 billion), representing an 11.9% YOY drop.","og_url":"https:\/\/flcube.com\/?p=39097","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-08-12T06:49:02+00:00","article_modified_time":"2025-08-12T06:49:03+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/1212.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=39097#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=39097"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Takeda Reports Q1 FY2025 Revenue Dip Led by FX Headwinds and Generic Competition","datePublished":"2025-08-12T06:49:02+00:00","dateModified":"2025-08-12T06:49:03+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=39097"},"wordCount":300,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=39097#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/1212.webp","keywords":["Finanical Reports","NYSE: TAK","Takeda","TYO: 4502"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=39097#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=39097","url":"https:\/\/flcube.com\/?p=39097","name":"Takeda Reports Q1 FY2025 Revenue Dip Led by FX Headwinds and Generic Competition - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=39097#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=39097#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/1212.webp","datePublished":"2025-08-12T06:49:02+00:00","dateModified":"2025-08-12T06:49:03+00:00","description":"Japan-based Takeda Pharmaceutical (TYO: 4502, NYSE: TAK)\u00a0 reported financial results for the first quarter of fiscal year 2025 (FY2025Q1, April 1, 2025~June 30, 2025). Revenue for the quarter decreased 3.7% year-over-year (YOY) at constant exchange rates (CER) to JPY 1,106.7 billion (USD 7.46 billion). Core operating profit was JPY 321.8 billion (USD 2.17 billion), representing an 11.9% YOY drop.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=39097#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=39097"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=39097#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/1212.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/1212.webp","width":1080,"height":608,"caption":"Takeda Reports Q1 FY2025 Revenue Dip Led by FX Headwinds and Generic Competition"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=39097#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Takeda Reports Q1 FY2025 Revenue Dip Led by FX Headwinds and Generic Competition"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/1212.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/39097","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=39097"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/39097\/revisions"}],"predecessor-version":[{"id":39102,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/39097\/revisions\/39102"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/39101"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=39097"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=39097"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=39097"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}